# Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia

> **NCT07270432** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ache Laboratorios Farmaceuticos S.A.** · enrollment: 218 (estimated)

## Conditions studied

- Prostatic Hyperplasia, Benign

## Interventions

- **DRUG:** Product DNN.65.21.005
- **DRUG:** Combodart®

## Key facts

- **NCT ID:** NCT07270432
- **Lead sponsor:** Ache Laboratorios Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07270432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07270432, "Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07270432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*